In recent years, highly effective, well-tolerated, all oraldirect-acting antiviral (DAA) therapies for hepatitis Cvirus (HCV) have raised the prospect of an era in whichHCV elimination is achievable worldwide. Globally, 71million individuals are estimated to be living with HCV.In 2016, the World Health Organization (WHO) issuedviral hepatitis elimination targets that include diagnosing90% of individuals living with HCV, initiating 80% ofthose who are eligible on treatment, and reducing incidenceby 90%. While the WHO’s goals have been mademore attainable due to the availability of these new effectivetherapies, recent modeling data suggest that 80%of high-income nations are not on track to achieve themby 2030 and nearly 70% are not expected to meet thembefore 2050 [1].
展开▼
